MUMBAI, India, March 13 -- Intellectual Property India has published a patent application (202641024850 A) filed by Vignan Institute Of Pharmaceutical Technology, Visakhapatnam, Andhra Pradesh, on March 2, for 'pharmacodynamic modelling of fungal-derived terpenoids in modulating gut-brain axis for anxiety disorders.'
Inventor(s) include M. Naga Bharathi; S. Kiranmai; R. Mohini; D. Rama Devi; and G. Vasantha.
The application for the patent was published on March 13, under issue no. 11/2026.
According to the abstract released by the Intellectual Property India: "This invention unveils an innovative modeling framework for fungal-derived terpenoids that target the gut-brain axis to alleviate anxiety disorders. By simulating the interactions of terpenoids extracted from fungi like Aspergillus or Penicillium with gut microbiota and neural pathways, the approach predicts their modulatory effects on serotonin production and inflammation reduction in the brain. Utilizing computational biology tools integrated with experimental validation, it identifies optimal terpenoid structures for enhanced bioavailability and efficacy. Distinct from conventional anxiolytics, this model emphasizes natural fungal compounds to restore gut dysbiosis linked to anxiety, showing in silico results of up to 55% improvement in anxiety symptom scores in virtual patient models. The invention offers a pathway for developing non-pharmacological interventions, with potential to minimize side effects like dependency, fostering personalized treatments based on individual microbiome profiles."
Disclaimer: Curated by HT Syndication.
